What does “urgency” mean when prioritizing cancer treatment? Results from a qualitative study with German oncologists and other experts during the COVID-19 pandemic.

Publication date: Jul 15, 2024

Cancer care in Germany during the COVID-19 pandemic was affected by resource scarcity and the necessity to prioritize medical measures. This study explores ethical criteria for prioritization and their application in cancer practices from the perspective of German oncologists and other experts. We conducted fourteen semi-structured interviews with German oncologists between February and July 2021 and fed findings of interviews and additional data on prioritizing cancer care into four structured group discussions, in January and February 2022, with 22 experts from medicine, nursing, law, ethics, health services research and health insurance. Interviews and group discussions were digitally recorded, transcribed verbatim and analyzed using qualitative content analysis. Narratives of the participants focus on “urgency” as most acceptable criterion for prioritization in cancer care. Patients who are considered curable and those with a high level of suffering, were given a high degree of “urgency. ” However, further analysis indicates that the “urgency” criterion needs to be further distinguished according to at least three different dimensions: “urgency” to (1) prevent imminent harm to life, (2) prevent future harm to life and (3) alleviate suffering. In addition, “urgency” is modulated by the “success,” which can be reached by means of an intervention, and the “likelihood” of reaching that success. Our analysis indicates that while “urgency” is a well-established criterion, its operationalization in the context of oncology is challenging. We argue that combined conceptual and clinical analyses are necessary for a sound application of the “urgency” criterion to prioritization in cancer care.

Open Access PDF

Concepts Keywords
Fourteen Adult
Germany Cancer care
July COVID-19
Medicine Empirical bioethics
Female
Germany
Health Priorities
Humans
Male
Medical Oncology
Middle Aged
Neoplasms
Oncologists
Pandemic
Pandemics
Prioritization criteria
Qualitative Research
Resource allocation
SARS-CoV-2
Urgency

Semantics

Type Source Name
disease MESH cancer
disease MESH COVID-19 pandemic
drug DRUGBANK Spinosad
disease IDO intervention
disease IDO history
drug DRUGBANK Etoperidone
disease IDO country
disease MESH death
disease IDO process
drug DRUGBANK Coenzyme M
drug DRUGBANK Ilex paraguariensis leaf
disease MESH leukemia
disease MESH carcinoma
disease MESH comorbidity
drug DRUGBANK Aspartame
drug DRUGBANK Trestolone
disease VO organ
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH emergencies
drug DRUGBANK Sulpiride
drug DRUGBANK Cysteamine
disease MESH hemorrhage
disease MESH uncertainty
drug DRUGBANK Pirenzepine
disease VO effective
drug DRUGBANK Carbamazepine
disease VO population
disease MESH SAMS
disease MESH burnout
disease VO vaccine
disease MESH Lung Cancer
disease MESH Pancreatic Cancer
pathway KEGG Pancreatic cancer
disease MESH noma
disease MESH Metastasis
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease VO report

Original Article

(Visited 3 times, 1 visits today)